Efficacy of Various Approaches to Treatment of Patients with Isoniazid Resistant Pulmonary Tuberculosis
https://doi.org/10.58838/2075-1230-2023-101-5-26-30
Abstract
The objective: to evaluate the efficacy of chemotherapy regimens for isoniazid resistant pulmonary tuberculosis (Hr-TB): short-course regimen consisting of 4 components (non-injection) and the regimen consisting of 5 components (standard regimen).
Subjects and Methods. Medical records of 292 pulmonary tuberculosis patients with resistance to isoniazid were retrospectively studied. In 89 patients (Group A), the regimen containing rifampicin, pyrazinamide, ethambutol, and levofloxacin was used – a 4-component non-injection regimen (180±20 doses). In 203 patients (Group B), the regimen containing rifampicin, pyrazinamide, ethambutol, levofloxacin, and amikacin/kanamycin was used - a 5-component standard regimen (270 doses).
Results. The efficacy of treatment of isoniazid resistant pulmonary tuberculosis was similar, while a short-term 4-component (non-injection) regimen is 4.5 times less expensive versus the standard 5-component regimen. Treatment success made 88.8% and 88.2% respectively, p>0.05.
About the Authors
I. A. BurmistrovaRussian Federation
Irina A. Burmistrova, Phthisiologist, Assistant of Phthisiology Department
4 Dostoevsky St., Moscow, 127473
Phone: +7 (495) 681-11-66
E. V. Vaniev
Russian Federation
Eduard V. Vaniev, Candidate of Medical Sciences, Phthisiologist Head of Therapy Department no. 2
4 Dostoevsky St., Moscow, 127473
Phone: +7 (495) 681-11-66
A. G. Samoylova
Russian Federation
Anastasiya G. Samoylova, Doctor of Medical Sciences, First Deputy Director
4 Dostoevsky St., Moscow, 127473
Phone: +7 (495) 681-11-66
O. V. Lovacheva
Russian Federation
Olga V. Lovacheva, Doctor of Medical Sciences, Professor, Chief Researcher
4 Dostoevsky St., Moscow, 127473
Phone: +7 (495) 681-11-66
I. A. Vasilyeva
Russian Federation
Irina A. Vasilyeva, Doctor of Medical Sciences, Professor, Director, Head of Phthisiology Department
4 Dostoevsky St., Moscow, 127473
Phone: +7 (495) 681-11-66
References
1. Burmistrova I.A., Vaniev E.V., Samoylova A.G., Lovacheva O.V., Vasilyeva I.A. Amplification of drug resistance against the background of inadequate chemotherapy for pulmonary tuberculosis. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 8, pp. 46-51. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-8-46-51.
2. Vasilyeva I.A., Belilovskiy E.M., Borisov S.E., Sterlikov S.A. Multiple drug resistant tuberculosis in the world and Russian Federation. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 11, pp. 5-17. (In Russ.) https://doi.org/10.21292/2075-1230-2017-95-11-5-17
3. Ivanova D.A.Nezhelatelnye reaktsii pri lechenii vpervye vyyavlennykh bolnykh tuberkulezom organov dykhaniya: profilaktika, rannyaya diagnostika i kupirovanie. Avtoref. diss. dokt. med. nauk. [Adverse reactions to treatment of new respiratory tuberculosis cases: prevention, early diagnostics and management. Synopsis of Doct. Diss.]. 14.01.16, Moscow, 2018, 41 p. Available: https://search.rsl.ru/ru/record/01008708323 Accessed October 10, 2023
4. Edict Russia no. 951 by RF MoH as of December 29, 2014 On Approval of Guidelines for Improvement of Respiratory Tuberculosis Diagnostics Treatment. (In Russ.) Available: https://minobr.permkrai.ru/dokumenty/40838/ Accessed September 30, 2023
5. Gegia M., Winters N., Benedetti A. et al. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect. Dis., 2017, vol. 17, no. 2, pp. 223-234.
6. Sagwa E., Mantel-Teeuwisse A.K., Ruswa N., Musasa J.P., Pal S., Dhliwayo P., van Wyk B. The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia. Southern Med. Review, 2012, vol. 5, no. 1, pp. 6-13.
7. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva, World Health Organization, 2019 (WHO/CDS/TB/2019.33). Available: https://www.who.int/publications/i/item/9789241550529 Accessed September 29, 2023
8. World Health Organization. WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis. Geneva, World Health Organization, 2018 (WHO/CDS/TB/2019.33). Available: https://www.who.int/publications/i/item/9789241550079 Accessed September 21, 2023
Review
For citations:
Burmistrova I.A., Vaniev E.V., Samoylova A.G., Lovacheva O.V., Vasilyeva I.A. Efficacy of Various Approaches to Treatment of Patients with Isoniazid Resistant Pulmonary Tuberculosis. Tuberculosis and Lung Diseases. 2023;101(5):26-30. (In Russ.) https://doi.org/10.58838/2075-1230-2023-101-5-26-30